[{"id":"76b3c565-76ec-4a35-a5f2-904c95dc1412","acronym":"","url":"https://clinicaltrials.gov/study/NCT04340427","created_at":"2021-01-18T21:00:30.735Z","updated_at":"2024-07-02T16:36:43.686Z","phase":"Phase 1","brief_title":"A Study of TQB3455 Tablets in Subjects With Advanced Malignancies","source_id_and_acronym":"NCT04340427","lead_sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","biomarkers":" IDH2","pipe":" | ","alterations":" IDH2 mutation","tags":["IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TQB3455"],"overall_status":"Unknown status","enrollment":" Enrollment 50","initiation":"Initiation: 04/10/2020","start_date":" 04/10/2020","primary_txt":" Primary completion: 06/30/2021","primary_completion_date":" 06/30/2021","study_txt":" Completion: 12/31/2021","study_completion_date":" 12/31/2021","last_update_posted":"2020-07-01"}]